The study in the Journal of the American Medical Association (JAMA) was funded by pharmaceutical giant Pfizer, which makes Chantix, but was led by doctors at the non-profit Mayo Clinic in Rochester, Minnesota.
More than 1,500 smokers enrolled. All said they were not ready to quit in the next 30 days, but did want to kick the habit within three months.
Researchers randomly assigned some to receive the drug for six months and others to receive a placebo.
After six months, those who received varenicline were more than four times more likely to quit than those who took a sugar pill -- 32.1 percent on the medication stopped smoking, compared to 6.9 percent of the placebo group.
After a year, those in the medication group were twice as likely to have quit than those in the placebo cohort. By that time, 27 percent on the medication had quit, versus 9.9 percent on the placebo.
The drug comes with side effects, ranging from nausea to thoughts of suicide, and did not help most of the smokers quit.
But researchers said their analysis showed it was more helpful than a placebo when it came to long-term habit changes.
"This study is important because this opens the door to treatment for approximately 14 million smokers who have no intention of quitting in the next 30 days but are willing to reduce their smoking rate while working toward a quit attempt," said lead author Jon Ebbert, associate director for research in the Mayo Clinic Nicotine Dependence Center.
"Smokers should know that varenicline can help them quit smoking if they want to reduce their smoking prior to completely stopping," he added.
"It's an effective and safe way to increase long-term smoking cessation."
Co-authors on the study came from the University of Vermont, University of London and Nebraska Medical Center.
source: interaksyon.com
